服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines. 产品介绍 Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
询价背景介绍 Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines. 产品介绍 Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
询价背景介绍 Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines. 产品介绍 Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
询价产品介绍 BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.
询价产品介绍 BAM7 is a direct and selective activator of BAX with IC50 value of 3.3 µM.
询价背景介绍 Unlike treatment with AZD 2281 (Olaparib, Axon 1464), AZD 2461 succesfully circumvents drug resistance of Pgp-proficient tumors, and inactivation of p53-binding protein 1 (53BP1) as a causal factor in PARPi resistance. 产品介绍 AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.
询价背景介绍 Unlike treatment with AZD 2281 (Olaparib, Axon 1464), AZD 2461 succesfully circumvents drug resistance of Pgp-proficient tumors, and inactivation of p53-binding protein 1 (53BP1) as a causal factor in PARPi resistance. 产品介绍 AZD2461 is a novel PARP inhibitor with low affinity for than Olaparib. AZD2641 is currently in Phase I clinical studies to treat solid tumors.
询价背景介绍 AR-42 induces histone H3 acetylation, α-tubulin acetylation and p21 up-regulation, which have been considered as the hallmark indicators of HDAC inhibition. AR-42 has been found to modulate several apoptosis inhibitors as well as cell survival regulator, including Akt, Bcl-xL, Bax, Ku70 and surviving, and exert potent antitumor activity against multiple tumor types, such as human prostate and hepatic cancers, at least partially through PI3K/Akt pathway inhibition. AR-42 has been designated an orphan drug by the FDA for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are rare, benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity. 产品介绍 AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
询价背景介绍 AR-42 induces histone H3 acetylation, α-tubulin acetylation and p21 up-regulation, which have been considered as the hallmark indicators of HDAC inhibition. AR-42 has been found to modulate several apoptosis inhibitors as well as cell survival regulator, including Akt, Bcl-xL, Bax, Ku70 and surviving, and exert potent antitumor activity against multiple tumor types, such as human prostate and hepatic cancers, at least partially through PI3K/Akt pathway inhibition. AR-42 has been designated an orphan drug by the FDA for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are rare, benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity. 产品介绍 AR-42 (also known as OSU-HDAC42), a derivative of hydroxamate-tethered phenylbutyrate is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins. AR-42 treatment induces histone hyperacetylation and p21WAF/CIP1 overexpression, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
询价
